{"schema_version":"secwatch.filing_event.v1","accession":"0001837607-25-000027","form_type":"8-K","ticker":"AEON","cik":"0001837607","company_name":"AEON Biopharma, Inc.","filed_at":"2025-04-08T23:59:59+00:00","discovered_at":"2026-05-14T18:02:50.046891+00:00","generated_at":"2026-05-23T19:08:53.717758+00:00","sec_items":["5.02"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"confidence":"high","headline":"AEON Biopharma appoints Jost Fischer Interim CEO and Jennifer Sy as principal financial officer","bullets":["On April 3, 2025, Board formally appointed Jost Fischer as Interim President, CEO and principal executive officer, effective April 4, 2025.","Board appointed Jennifer Sy as Chief Accounting Officer and principal financial officer, effective April 4, 2025.","Ms. Sy previously served as VP, Corporate Controller since August 2023; base salary increased to $275,000 from $245,000.","Mr. Fischer continues as Chairman of the Board; no other compensation changes disclosed."],"urls":{"canonical":"https://secwatch.observer/filing/0001837607-25-000027","json":"https://secwatch.observer/filing/0001837607-25-000027.json","markdown":"https://secwatch.observer/filing/0001837607-25-000027.md","text":"https://secwatch.observer/filing/0001837607-25-000027.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1837607/000183760725000027/0001837607-25-000027-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1837607/000183760725000027/aeon-20250403x8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-23T19:08:53.717758+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"1059e422b1","claim":"Jennifer Sy was appointed as Chief Accounting Officer and principal financial officer at AEON Biopharma, Inc..","evidence_excerpt":"On April 3, 2025, the Board appointed Jennifer Sy, age 40, as the Company’s Chief Accounting Officer and principal financial officer, effective as of April 4, 2025.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1837607/000183760725000027/0001837607-25-000027-index.htm","confidence":1.0,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Chief Accounting Officer and principal financial officer"}]},{"claim_id":"d5188e33a3","claim":"Jost Fischer was appointed as Interim President, Chief Executive Officer and principal executive officer at AEON Biopharma, Inc..","evidence_excerpt":"On April 3, 2025, the Board formally appointed Mr. Fischer to serve as Interim President, Chief Executive Officer and principal executive officer of the Company, effective as of April 4, 2025.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1837607/000183760725000027/0001837607-25-000027-index.htm","confidence":1.0,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Interim President, Chief Executive Officer and principal executive officer"}]}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}